OP22. FDG-PET SCANNING

18F-FDG PET scanning in pulmonary amyloidosis.

UNLABELLED (18)F-FDG PET plays an important role in the evaluation of patients with lung malignancies but can lead to false-positive and false-negative results. Very little is known about (18)F-FDG PET scanning in amyloidosis. METHODS A computer-assisted search of medical records was conducted to identify subjects with pulmonary amyloidosis (confirmed by biopsy) who were seen at the Mayo Clin...

Utility of FDG-PET scanning in lymphoma by WHO classification.

We retrospectively evaluated (18)fluoro-2-deoxyglucose positron emission tomography (FDG-PET) scans in 172 patients with lymphoma and correlated results with pathologic diagnosis using the World Health Organization (WHO) classification system. In total, FDG-PET detected disease in at least one site in 161 patients (94%) and failed to detect disease in 11 patients (6%). The most frequent lymphom...

Scar sarcoidosis on 18F-FDG PET/CT

18F-labeled fluoro-2-deoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) is an important imaging modality in the clinical workup of patients with chronic inflammatory disorders which present quite often with a fever of unknown origin. Sarcoidosis is a multisystem chronic inflammatory disorder with a wide clinical spectrum that can involve different organs. The diagno...

[ 18 F ] Fdg - Pet

FDG PET reimbursement.

Today, PET is increasingly accepted as a crucial imaging modality for early detection of disease, precise staging of disease progression, and accurate assessment of the effects of therapy. As the role of PET continues to emerge, so do questions regarding PET reimbursement. Understanding the complexities and complying with reimbursement policies, procedures, and interpretation of payer programs ...